To view this email as a web page, click here.

You are subscribed to the FormularyWatch eNews.

FormularyWatch

Share

eNews Subscribe

More Subscriptions

FORMULARY WATCH

CANCER

TODAY'S HEADLINES

Cancer drug makers overcharging at a shocking rate

By Christine Blank
Analysis shows cancer drugs are shockingly overpriced and Americans are paying more than double the price charged in Europe for the tyrosine kinase inhibitors (TKIs). Details

Keytruda for lung cancer gets accelerated approval

by Christine Blank
FDA granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Specific patient target

CONTINUING EDUCATION

MTM essentials for allergic rhinitis management

Session code: 15DT34-XVK37
This month’s CE activity is part of the CPE series, "Medication Therapy Management for the Patient with Respiratory Disease." From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and  Drug Topics.

The goal of this month's activity is to discuss the pathophysiology and clinical presentation of allergic rhinitis and review nonpharmacologic and pharmacologic treatments for the symptoms of allergic rhinitis.

To read and print the article with TEST QUESTIONS,  click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT34-XVK37.
Copy the session code — 15DT34-XVK37 — before logging into the  Online CE Center. When the page for the Online CE Center opens, paste the session code into the appropriate field, under your NABP ID.

EDITOR'S PICK

Campaign aims to increase global awareness of IPF

by Christine Blank
Healthcare providers, celebrities, patients and others are helping to increase awareness of idiopathic pulmonary fibrosis (IPF). Find out more

October 07, 2015

Related Articles

Why new lung cancer drug approval is important

Studies: Zykadia shrank tumors in patients with ALK+ NSCLC

Resources

Get the latest FormularyWatch updates on drug approvals, current studies, and other findings.

Click for the latest Clinical News

Click to contact the editorial team. Click to contact the sales team.

Part of the

ModernMedicine logo

This email was sent by: %%Member_Busname%%
%%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%

 

NEWSLETTER

Forward to a Friend
Privacy Statement
Terms of Service
Update Profile
Add/Remove Newsletters